A Phase 1 interventional study of Cobimetinib and GDC-0994 in Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma, sponsored by Genentech, Inc.. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-20.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche — 5 open to participants now, 16 under way, 8 of them phase 3. Carcinoma, Non-Small-Cell Lung · Hoffmann-La Roche.
Among the 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche, this one is the 120th largest by enrollment of the 142 interventional ones that give a count, is one of 9 that started in 2015, is one of 19 in phase 1, and was the 108th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →5 of the 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States, Argentina, Belgium and 16 more countries
Ages 18+
Chugai Pharmaceutical · Sites in United States, Japan
Ages 18+
Hoffmann-La Roche · Sites in United States, Argentina, Australia and 25 more countries
Ages 18+
Hoffmann-La Roche · Sites in China
Ages 18+
Hoffmann-La Roche · Sites in United States, Argentina, Australia and 15 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
182 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 66 · Phase 3 50 · Phase 4 10
First in 2001; this study’s year is marked. 9 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 136 across the 142 interventional studies, 289 across the 37 observational. Of the 161 that completed or were terminated, 96 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
5 of the studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05170204Phase 3Hoffmann-La RocheA Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) | 2027-01-19 |
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
| NCT04302025Genentech, Inc.A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) | 2026-11-30 |
| NCT04140500Hoffmann-La RocheDose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors | 2027-06-30 |
| NCT02568267Hoffmann-La RocheBasket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | 2027-06-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a two-stage dose-escalation study to assess the safety, tolerability and effects of oral dosing of cobimetinib and GDC-0994 administered in combination in patients with histologically confirmed, locally advanced, or metastatic solid tumors for which standard therapies either do not exist or have proven ineffective or intolerable.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For enrollment in part 2, patients must meet all of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One participant was assigned to receive intermittent cobimetinib 80 milligrams (mg) + GDC 0994 200 mg) and did receive study drug. However, the participant diary was not returned, and the site was unable to document study dose administration.
Drug: Cobimetinib · Drug: GDC-0994
Concurrent or intermittent dosing of cobimetinib 20 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
Drug: Cobimetinib · Drug: GDC-0994
Concurrent or intermittent dosing of cobimetinib 40 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
Drug: Cobimetinib · Drug: GDC-0994
Concurrent or intermittent dosing of cobimetinib 80 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
Drug: Cobimetinib · Drug: GDC-0994
Concurrent or intermittent dosing of cobimetinib 80 mg, concurrent with GDC-0994 400 mg for 21 consecutive days, followed by 7 days off.
Drug: Cobimetinib · Drug: GDC-0994
Concurrent or intermittent dosing of cobimetinib 100 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
Drug: Cobimetinib · Drug: GDC-0994
Cobimetinib given concurrently or intermittently with GDC-0994 for 21 consecutive days followed by 7 days off.
GDC-0994 given for 21 consecutive days followed by 7 days off, along with concurrent or intermittent dosing of cobimetinib.
Number of Participants With Dose-Limiting Toxicities (DLTs)
DLTs include symptoms considered by the investigator to be possibly related to study drug.
Time frame: 28 days (Cycle 1)
Percentage of Participants With at Least One Adverse Event
An adverse event is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution.
Time frame: Up to 15 months
Percentage of Participants With at Least One Adverse Event of Special Interest
AESIs were graded per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v4.0. AESIs included the following: Grade ≥ 1 retinal vein occlusion; Grade ≥ 2 visual disturbances (including events suggestive of serous retinopathy); Grade ≥ 3 rash for \> 7 days; Grade ≥ 3 diarrhea for \> 3 days; Grade ≥ 2 left ventricular ejection fraction (LVEF) decrease; Grade 3 hepatotoxicity; any dose-limiting toxicity (DLT); cases of potential drug-induced liver injury that include an elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) (AST \> 3 × baseline value \[and above the upper limit of normal, ULN\]) in combination with either an elevated bilirubin ( \> 2 × ULN) or clinical jaundice; or suspected transmission of an infectious agent by either study drug.
Time frame: Up to 15 months
Percentage of Participants With at Least One Serious Adverse Event (SAE)
A SAE is any experience that: results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is medically significant.
Time frame: Up to 15 months
Percentage of Participants With Laboratory Abnormalities
Laboratory abnormalities were graded per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v4.0. SGPT/ALT - serum glutamic-pyruvic transaminase/alanine aminotransferase; SGOT/AST - serum glutamic oxaloacetic transaminase/aspartate aminotransferase
Time frame: Up to 15 months
Mean Change From Baseline in Diastolic Blood Pressure
Time frame: Baseline, up to 15 months
Mean Change From Baseline in Lean Body Mass
Time frame: Baseline, Day 15
Mean Change From Baseline in Pulse Rate
Time frame: Baseline, up to 15 months
Mean Change From Baseline in Respiratory Rate
Time frame: Baseline, up to 15 months
Mean Change From Baseline in Systolic Blood Pressure
Time frame: Baseline, up to 15 months
Mean Change From Baseline in Temperature
Time frame: Baseline, up to 15 months
Mean Change From Baseline in Weight
Time frame: Baseline, up to 15 months
Maximum Serum Concentration (Cmax) for GDC-0994
Time frame: Up to Day 22
Median Time to Maximum Serum Concentration (Tmax) for GDC-0994
Time frame: Up to Day 22
Maximum Serum Concentration (Cmax) for Cobimetinib
Time frame: Up to Day 22
Median Time to Maximum Serum Concentration (Tmax) for Cobimetinib
Time frame: Up to Day 22
Total Exposure (AUC From Time 0 to 24 Hour After Dose) for GDC-0994
Data are reported for evaluable participants.
Time frame: 0 to 24 hours post-dose (Up to Day 22)
Total Exposure (AUC From Time 0 to 24 Hour After Dose) for Cobimetinib
Time frame: 0 to 24 hours post-dose (Up to Day 22)
Mean Accumulation Ratio
Time frame: Pre-dose Day 1 Cycle 1, 2, 3, Day 18, 21 Cycle 1; post-dose 0.5, 1, 2, 3, 4, 6 hours Day 1, 18, 21 Cycle 1; Day 2, 15, 19, 22, Cycle 1
Mean Terminal Half-life (t1/2)
Time frame: Up to day 22 of study
Change From Baseline in Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
Time frame: Baseline, Day 15
Change From Baseline in Tumor Tissue Biomarkers
Time frame: Up to 15 months
| Milestone | Not Assigned | COB 20 mg + GDC 200 mg | COB 40 mg + GDC 200 mg | COB 80 mg + GDC 200 mg | COB 80 mg + GDC 400 mg | COB 100 mg + GDC 200 mg |
|---|---|---|---|---|---|---|
| Started | 1 | 5 | 3 | 5 | 4 | 6 |
| Completed | 0 | 1 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 4 | 3 | 5 | 4 | 6 |
| Withdrew: Reason not specified | 0 | 0 | 0 | 1 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 4 | 2 | 2 | 2 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 1 | 1 | 1 | 3 |
DLTs include symptoms considered by the investigator to be possibly related to study drug.
| Participants | Not Assigned | COB 20 mg + GDC 200 mg | COB 40 mg + GDC 200 mg | COB 80 mg + GDC 200 mg | COB 80 mg + GDC 400 mg | COB 100 mg + GDC 200 mg |
|---|---|---|---|---|---|---|
| Dermatitis Acneiform | 1 | 0 | 0 | 0 | 0 | 0 |
| Rash | 1 | 0 | 0 | 0 | 0 | 0 |
| Diarrhoea | 0 | 0 | 1 | 0 | 0 | 0 |
| Myocardial infarction | 0 | 0 | 0 | 1 | 0 | 0 |
An adverse event is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution.
| percentage of participants | Not Assigned | COB 20 mg + GDC 200 mg | COB 40 mg + GDC 200 mg | COB 80 mg + GDC 200 mg | COB 80 mg + GDC 400 mg | COB 100 mg + GDC 200 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants With at Least One Adverse Event | 100 | 100 | 100 | 100 | 100 | 100 |
AESIs were graded per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v4.0. AESIs included the following: Grade ≥ 1 retinal vein occlusion; Grade ≥ 2 visual disturbances (including events suggestive of serous retinopathy); Grade ≥ 3 rash for \> 7 days; Grade ≥ 3 diarrhea for \> 3 days; Grade ≥ 2 left ventricular ejection fraction (LVEF) decrease; Grade 3 hepatotoxicity; any dose-limiting toxicity (DLT); cases of potential drug-induced liver injury that include an elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) (AST \> 3 × baseline value \[and above the upper limit of normal, ULN\]) in combination with either an elevated bilirubin ( \> 2 × ULN) or clinical jaundice; or suspected transmission of an infectious agent by either study drug.
| percentage of participants | Not Assigned | COB 20 mg + GDC 200 mg | COB 40 mg + GDC 200 mg | COB 80 mg + GDC 200 mg | COB 80 mg + GDC 400 mg | COB 100 mg + GDC 200 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants With at Least One Adverse Event of Special Interest | 100.0 | 100 | 33.3 | 60.0 | 75.0 | 50.0 |
A SAE is any experience that: results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is medically significant.
| percentage of participants | Not Assigned | COB 20 mg + GDC 200 mg | COB 40 mg + GDC 200 mg | COB 80 mg + GDC 200 mg | COB 80 mg + GDC 400 mg | COB 100 mg + GDC 200 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants With at Least One Serious Adverse Event (SAE) | 100.0 | 40.0 | 66.7 | 60.0 | 50.0 | 66.7 |
Laboratory abnormalities were graded per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v4.0. SGPT/ALT - serum glutamic-pyruvic transaminase/alanine aminotransferase; SGOT/AST - serum glutamic oxaloacetic transaminase/aspartate aminotransferase
| percentage of participants | Not Assigned | COB 20 mg + GDC 200 mg | COB 40 mg + GDC 200 mg | COB 80 mg + GDC 200 mg | COB 80 mg + GDC 400 mg | COB 100 mg + GDC 200 mg |
|---|---|---|---|---|---|---|
| Albumin | 100.0 | 80.0 | 66.7 | 100.0 | 100.0 | 83.3 |
| Alkaline Phosphatase | 100.0 | 80.0 | 66.7 | 80.0 | 75.0 | 50.0 |
| SGPT/ALT | 0.0 | 60.0 | 0.0 | 60.0 | 25.0 | 33.3 |
| SGOT/AST | 100.0 | 100.0 | 66.7 | 60.0 | 75.0 | 50.0 |
| Calcium | 100.0 | 20.0 | 33.3 | 80.0 | 100.0 | 33.3 |
| Creatinine | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 50.0 |
| Blood Glucose, Fasting | 0.0 | 100.0 | 100.0 | 0.0 | 66.6 | 100.0 |
| Gamma Glutamyl Transferase | 100.0 | 60.0 | 66.7 | 60.0 | 75.0 | 50.0 |
| Glucose | 0 | 20.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Hemoglobin | 100.0 | 60.0 | 66.7 | 100.0 | 75.0 | 66.7 |
| Lymphocytes, Absolute | 100.0 | 40.0 | 33.3 | 60.0 | 50.0 | 16.7 |
| Magnesium | 100.0 | 40.0 | 66.6 | 20.0 | 50.0 | 16.7 |
| Phosphorus | 0.0 | 20.0 | 0.0 | 0.0 | 25.0 | 0.0 |
| Platelets | 0.0 | 20.0 | 33.3 | 40.0 | 50.0 | 33.3 |
| Potassium | 0.0 | 40.0 | 66.7 | 40.0 | 25.0 | 33.3 |
| Sodium | 0.0 | 60.0 | 33.3 | 0.0 | 50.0 | 16.7 |
| Bilirubin | 100.0 | 20.0 | 0.0 | 0.0 | 25.0 | 0.0 |
| Uric Acid | 0.0 | 20.0 | 0.0 | 0.0 | 25.0 | 16.7 |
| White Blood Cell Count | 0.0 | 20 | 0.0 | 20.0 | 25.0 | 33.3 |
| millimeters of mercury (mmHg) | Not Assigned | COB 20 mg + GDC 200 mg | COB 40 mg + GDC 200 mg | COB 80 mg + GDC 200 mg | COB 80 mg + GDC 400 mg | COB 100 mg + GDC 200 mg |
|---|---|---|---|---|---|---|
| Mean Change From Baseline in Diastolic Blood Pressure | — | -4.2 ± 7.6 | -4.3 ± 11.8 | -0.5 ± 7.8 | 29.0 | -13.2 ± 15.9 |
| kilograms (kg) | Not Assigned | COB 20 mg + GDC 200 mg | COB 40 mg + GDC 200 mg | COB 80 mg + GDC 200 mg | COB 80 mg + GDC 400 mg | COB 100 mg + GDC 200 mg |
|---|---|---|---|---|---|---|
| Mean Change From Baseline in Lean Body Mass | — | 0.25 ± 1.26 | -2.00 | -0.20 ± 1.30 | -4.33 ± 5.77 | 0.00 ± 1.41 |
| beats per minute | Not Assigned | COB 20 mg + GDC 200 mg | COB 40 mg + GDC 200 mg | COB 80 mg + GDC 200 mg | COB 80 mg + GDC 400 mg | COB 100 mg + GDC 200 mg |
|---|---|---|---|---|---|---|
| Mean Change From Baseline in Pulse Rate | — | 20.4 ± 32.7 | 16.7 ± 22.7 | 15.5 ± 9.2 | 43.0 | 12.2 ± 21.6 |
| breaths per minute | Not Assigned | COB 20 mg + GDC 200 mg | COB 40 mg + GDC 200 mg | COB 80 mg + GDC 200 mg | COB 80 mg + GDC 400 mg | COB 100 mg + GDC 200 mg |
|---|---|---|---|---|---|---|
| Mean Change From Baseline in Respiratory Rate | — | 1.6 ± 3.6 | 0.3 ± 0.6 | 0.0 ± 0.0 | 2.0 | 1.6 ± 3.6 |
| mmHg | Not Assigned | COB 20 mg + GDC 200 mg | COB 40 mg + GDC 200 mg | COB 80 mg + GDC 200 mg | COB 80 mg + GDC 400 mg | COB 100 mg + GDC 200 mg |
|---|---|---|---|---|---|---|
| Mean Change From Baseline in Systolic Blood Pressure | — | 2.2 ± 19.6 | -4.0 ± 30.6 | -1.5 ± 0.7 | 34.0 | -17.2 ± 20.9 |
| degrees Celsius | Not Assigned | COB 20 mg + GDC 200 mg | COB 40 mg + GDC 200 mg | COB 80 mg + GDC 200 mg | COB 80 mg + GDC 400 mg | COB 100 mg + GDC 200 mg |
|---|---|---|---|---|---|---|
| Mean Change From Baseline in Temperature | — | -0.04 ± 0.31 | -0.20 ± 0.87 | -0.16 ± 0.20 | -0.20 | -0.16 ± 0.34 |
| kg | Not Assigned | COB 20 mg + GDC 200 mg | COB 40 mg + GDC 200 mg | COB 80 mg + GDC 200 mg | COB 80 mg + GDC 400 mg | COB 100 mg + GDC 200 mg |
|---|---|---|---|---|---|---|
| Mean Change From Baseline in Weight | — | -4.01 ± 7.71 | 0.33 ± 1.69 | 0.57 ± 3.34 | -2.70 | -0.80 ± 3.43 |
| micromoles | COB 80 mg + GDC 300 mg | COB 20 mg + GDC 200 mg | COB 40 mg + GDC 200 mg | COB 80 mg + GDC 200 mg | COB 80 mg + GDC 400 mg | COB 100 mg + GDC 200 mg |
|---|---|---|---|---|---|---|
| Day 1 | — | 2.51 ± 54.6 | 2.08 ± 68.4 | 2.02 ± 109.0 | 2.42 ± 33.6 | 2.56 ± 77.8 |
| Steady State | 2.56 | 1.80 ± 74.2 | 2.01 ± 0.0 | 2.26 ± 23.1 | 2.09 ± 0.0 | 2.36 ± 28.2 |
| hours | COB 80 mg + GDC 300 mg | COB 20 mg + GDC 200 mg | COB 40 mg + GDC 200 mg | COB 80 mg + GDC 200 mg | COB 80 mg + GDC 400 mg | COB 100 mg + GDC 200 mg |
|---|---|---|---|---|---|---|
| Day 1 | — | 4.00 (2.00 to 6.00) | 6.00 (2.00 to 6.00) | 3.00 (2.00 to 24.0) | 15.0 (2.0 to 24.0) | 2.50 (1.00 to 4.00) |
| Steady State | 3.00 | 3.00 (2.00 to 4.00) | 24.0 | 2.00 (2.00 to 3.00) | 3.00 | 2.00 (2.00 to 2.00) |
| nanograms per milliliter (ng/mL) | COB 80 mg + GDC 300 mg | COB 20 mg + GDC 200 mg | COB 40 mg + GDC 200 mg | COB 80 mg + GDC 200 mg | COB 80 mg + GDC 400 mg | COB 100 mg + GDC 200 mg |
|---|---|---|---|---|---|---|
| Day 1 | — | 41.8 ± 102.0 | 90.2 ± 60.9 | 392 ± 31.9 | 155 ± 52.5 | 384 ± 53.2 |
| Steady State | 73.0 | 48.5 ± 121.0 | 204 | 399 ± 46.4 | 284 | 431 ± 63.3 |
| hours | COB 80 mg + GDC 300 mg | COB 20 mg + GDC 200 mg | COB 40 mg + GDC 200 mg | COB 80 mg + GDC 200 mg | COB 80 mg + GDC 400 mg | COB 100 mg + GDC 200 mg |
|---|---|---|---|---|---|---|
| Day 1 | — | 2.00 (2.00 to 4.00) | 2.00 (1.00 to 3.00) | 2.00 (1.00 to 3.00) | 4.00 (2.00 to 6.00) | 2.00 (1.00 to 3.00) |
| Steady State | 1.00 | 1.50 (1.00 to 2.00) | 24.0 | 1.00 (0.500 to 2.00) | 2.00 | 2.00 (2.00 to 2.00) |
Data are reported for evaluable participants.
| hr x microM | COB 80 mg + GDC 300 mg | COB 20 mg + GDC 200 mg | COB 40 mg + GDC 200 mg | COB 80 mg + GDC 200 mg | COB 80 mg + GDC 400 mg | COB 100 mg + GDC 200 mg |
|---|---|---|---|---|---|---|
| Day 1 | — | 37.0 ± 45.9 | 32.9 ± 55.4 | 27.9 ± 93.8 | 37.8 ± 37.5 | 37.7 ± 81.0 |
| Steady State | 48.3 | 23.5 ± 73.4 | 24.1 | 33.3 ± 66.4 | 37.2 | 34.0 |
| ng x hr/mL | COB 80 mg + GDC 300 mg | COB 20 mg + GDC 200 mg | COB 40 mg + GDC 200 mg | COB 80 mg + GDC 200 mg | COB 80 mg + GDC 400 mg | COB 100 mg + GDC 200 mg |
|---|---|---|---|---|---|---|
| Day 1 | — | 501 ± 121.0 | 1020 ± 33.9 | 4420 ± 25.5 | 2460 ± 50.9 | 4060 ± 74.3 |
| Steady State | 908 | 508 ± 255.0 | 2460 | 4320 ± 37.4 | 3410 | 4070 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Collected over 15 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Not Assigned | — | 1/1 (100%) | 1/1 (100%) |
| COB 20 mg + GDC 200 mg | — | 2/5 (40%) | 5/5 (100%) |
| COB 40 mg + GDC 200 mg | — | 2/3 (66.7%) | 3/3 (100%) |
| COB 80 mg + GDC 200 mg | — | 3/5 (60%) | 5/5 (100%) |
| COB 80 mg + GDC 400 mg | — | 2/4 (50%) | 4/4 (100%) |
| COB 100 mg + GDC 200 mg | — | 4/6 (66.7%) | 6/6 (100%) |
| Event | Not Assigned | COB 20 mg + GDC 200 mg | COB 40 mg + GDC 200 mg | COB 80 mg + GDC 200 mg | COB 80 mg + GDC 400 mg | COB 100 mg + GDC 200 mg |
|---|---|---|---|---|---|---|
| ABDOMINAL PAINGastrointestinal disorders | 1/1 | 0/5 | 0/3 | 0/5 | 0/4 | 0/6 |
| PNEUMONIA VIRALInfections and infestations | 1/1 | 0/5 | 0/3 | 0/5 | 0/4 | 0/6 |
| HYPOXIARespiratory, thoracic and mediastinal disorders | 1/1 | 0/5 | 0/3 | 0/5 | 0/4 | 0/6 |
| DIARRHOEAGastrointestinal disorders | 0/1 | 0/5 | 1/3 | 0/5 | 0/4 | 1/6 |
| ANAEMIABlood and lymphatic system disorders | 0/1 | 0/5 | 1/3 | 0/5 | 0/4 | 0/6 |
| DYSPHAGIAGastrointestinal disorders | 0/1 | 0/5 | 0/3 | 0/5 | 1/4 | 0/6 |
| NAUSEAGastrointestinal disorders | 0/1 | 0/5 | 0/3 | 0/5 | 1/4 | 0/6 |
| OEDEMA PERIPHERALGeneral disorders | 0/1 | 0/5 | 0/3 | 0/5 | 1/4 | 0/6 |
| DEHYDRATIONMetabolism and nutrition disorders | 0/1 | 0/5 | 0/3 | 0/5 | 1/4 | 0/6 |
| COLITISGastrointestinal disorders | 0/1 | 0/5 | 0/3 | 1/5 | 0/4 | 0/6 |
| Event | Not Assigned | COB 20 mg + GDC 200 mg | COB 40 mg + GDC 200 mg | COB 80 mg + GDC 200 mg | COB 80 mg + GDC 400 mg | COB 100 mg + GDC 200 mg |
|---|---|---|---|---|---|---|
| DIARRHOEAGastrointestinal disorders | 1/1 | 4/5 | 2/3 | 5/5 | 4/4 | 4/6 |
| NAUSEAGastrointestinal disorders | 1/1 | 5/5 | 2/3 | 4/5 | 3/4 | 2/6 |
| VOMITINGGastrointestinal disorders | 1/1 | 3/5 | 1/3 | 5/5 | 3/4 | 3/6 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 1/1 | 1/5 | 0/3 | 1/5 | 1/4 | 1/6 |
| DERMATITIS ACNEIFORMSkin and subcutaneous tissue disorders | 1/1 | 2/5 | 2/3 | 1/5 | 4/4 | 1/6 |
| RASHSkin and subcutaneous tissue disorders | 1/1 | 1/5 | 1/3 | 0/5 | 0/4 | 1/6 |
| FATIGUEGeneral disorders | 0/1 | 4/5 | 1/3 | 2/5 | 2/4 | 3/6 |
| VISION BLURREDEye disorders | 0/1 | 2/5 | 1/3 | 0/5 | 3/4 | 1/6 |
| HAEMATOCHEZIAGastrointestinal disorders | 0/1 | 1/5 | 2/3 | 0/5 | 0/4 | 0/6 |
| ASTHENIAGeneral disorders | 0/1 | 3/5 | 2/3 | 0/5 | 1/4 | 0/6 |
| Age, Continuous(Years) | Not Assigned | COB 20 mg + GDC 200 mg | COB 40 mg + GDC 200 mg | COB 80 mg + GDC 200 mg | COB 80 mg + GDC 400 mg | COB 100 mg + GDC 200 mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 48.0 ± 9999 | 53.0 ± 11.5 | 57.3 ± 11.0 | 51.6 ± 14.2 | 52.3 ± 5.6 | 59.7 ± 11.5 | 54.6 ± 10.7 |
| Sex: Female, Male(Participants) | Not Assigned | COB 20 mg + GDC 200 mg | COB 40 mg + GDC 200 mg | COB 80 mg + GDC 200 mg | COB 80 mg + GDC 400 mg | COB 100 mg + GDC 200 mg | Total |
|---|---|---|---|---|---|---|---|
| Female | 0 | 5 | 3 | 4 | 2 | 3 | 17 |
| Male | 1 | 0 | 0 | 1 | 2 | 3 | 7 |
Ran from Jun 2015 to primary completion in Dec 2016, 17 months.
Results were first posted in Aug 2018, 1 year 8 months after primary completion.
Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 17 months is below that.
Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cobimetinib
Carcinoma, Non-Small-Cell Lung →